Compounds of formula (I)wherein: X is N;R1 is C1–C6 linear or branched
alkyl or C1–C6 linear or branched alkenyl; R2 is
hydrogen, C1–C6 linear or branched
alkyl or C1–C6 linear or branched alkenyl, C6–C14
aryl or C6–C14
aryl(C1–C6) linear or branched
alkyl or C6–C14
aryl(C1–C6) linear or branched alkenyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting of
halogen, hydroxy, C1–C6 alkoxy linear or branched or C114 C6 alkenyloxy linear or branched, amino, optionally mono- or disubstituted with C1–C6 linear or branched alkyl; R3 is NH2, NHR4; R4 is C1–C6 alkyl or C1–C6 hydroxyalkyl, C1–C3 alkoxyalkyl, amino(C1–C6)alkyl, where the amino group is optionally substituted with one or two C1–C3 linear or branched alkyl groups, or with one or two C2–C3 alkenyl groups C6–C14 aryl or C6–C14 aryl(C1–C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting by
halogen, hydroxy, C1–C6 alkoxy linear or branched or C1–C6 alkenyloxy linear or branched, amino, mono- or di-substituted with C1–C6 alkyl linear or branched or C1–C6 alkenyl linear or branched; and their pharmaceutically acceptable salts. These compounds are antagonists of the
adenosine A2a
receptor and useful as medicaments, in particular for the treatment of Parkinson's
disease.